How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View
Daniela E. Oprea‐Lager(Amsterdam University Medical Centers), Niven Mehra(Royal Marsden NHS Foundation Trust), Jules Lavalaye(St. Antonius Ziekenhuis), Peter-Paul Willemse(European Association of Urology), Joyce M. van Dodewaard-de Jong, Robert J. van Soest(Sint Franciscus Gasthuis), Walter Noordzij, Henk G. van der Poel(Amsterdam University Medical Centers), Igle J. de Jong(University of Groningen), Aart Beeker(Spaarne Ziekenhuis), Els Dewulf, Michel van Kruchten(University Medical Center Groningen), Theo Veninga(Instituut Verbeeten), E. Van Limbergen(Maastricht University Medical Centre), R. Jeroen A. van Moorselaar(Amsterdam UMC Location Vrije Universiteit Amsterdam), Maarten L. Donswijk(The Netherlands Cancer Institute), Kim C. de Vries(Erasmus MC), Robert J. Hoekstra(Radboud University Nijmegen), Thomas Kerkhofs(Radboud University Nijmegen), Jurgen J. Fütterer(Radboud University Nijmegen), Irma M. Oving, Paul Hamberg(Sint Franciscus Gasthuis), Pim J. van Leeuwen(Ghent University Hospital), Linda Heijmen(Leiden University Medical Center), Roderick C.N. van den Bergh(Erasmus MC), Steve Boudewijns(Bravis Ziekenhuis), Shafak Aluwini(Erasmus MC Cancer Institute), Joep G.H. van Roermund(Maasstad Ziekenhuis), Herman Stoevelaar(Barnes-Jewish Hospital), Derya Yakar(Dialyse Centrum Groningen), Debbie Robbrecht(Erasmus MC), Inge M. van Oort(University Medical Center Groningen), André N. Vis(Hôpitaux Universitaires Henri-Mondor), Daphne Luijendijk-de Bruin(Martini Ziekenhuis), Tom van der Hulle, Jens Voortman(Vrije Universiteit Amsterdam), Addy C.M. van de Luijtgaarden(Prostate Cancer UK), J C Koen van der Mijn(The Netherlands Cancer Institute), Franchette van den Berkmortel, Tom Budiharto(Radboud University Nijmegen), Chris H. Bangma(Erasmus MC), Eva E. Schaake(The Netherlands Cancer Institute), Tessa van Elst(Radboud University Nijmegen)
Cited by 4
Related Papers
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
|The Lancet Oncology|2015|380